Collection 4 (Sep 2023 - Aug 2024) Articles

Articles
Association of cardiovascular health with subclinical coronary atherosclerosis progression among five racial and ethnic groups: The MASALA and MESA studies
Jain V, Rifai MA, Kanaya AM, et al.
Journal:
Atherosclerosis

First published: March 17, 2024 DOI: 10.1016/j.atherosclerosis.2024.117522
View
- Share
Articles
Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study
Alonso R, Arroyo-Olivares R, Díaz-Díaz JL, et al.
Journal:
Atherosclerosis

First published: March 16, 2024 DOI: 10.1016/j.atherosclerosis.2024.117516
View
- Share
Articles
Oral PCSK9 Inhibitors
Agarwala A, Asim R, Ballantyne CM
Journal:
Curr Atheroscler Rep

First published: March 13, 2024 DOI: 10.1007/s11883-024-01199-2
View
- Share
Articles
European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges
3Pirillo A, Tokgözoğlu L, Catapano AL
Journal:
Curr Atheroscler Rep

First published: March 2, 2024 DOI: 10.1007/s11883-024-01194-7
View
- Share
Articles
Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
Thau H, Neuber S, Emmert MY, et al.
Journal:
Cardiol Ther

First published: February 21, 2024 DOI: 10.1007/s40119-024-00353-w
View
- Share
Articles
Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials
Xie S, Galimberti F, Olmastroni E, et al.
Journal:
Cardiovasc Res

First published: February 19, 2024 DOI: 10.1093/cvr/cvae034
View
- Share
Articles
Assessing the Role of Bempedoic Acid in Lipid-Lowering Therapy
Fernandez-Vazquez D, Weideman S, Banerjee S
Journal:
Am J Cardiol

First published: February 16, 2024 DOI: 10.1016/j.amjcard.2024.02.002
View
- Share
Articles
Impact of the 2021 ESC Prevention Guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established ASCVD
Holtrop J, Bhatt DL, Ray KK, et al.
Journal:
Eur J Prev Cardiol

First published: February 7, 2024 DOI: 10.1093/eurjpc/zwae038
View
- Share
Articles
Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Bétrisey S, Haller ML, Efthimiou O, et al.
Journal:
J Am Heart Assoc

First published: February 7, 2024 DOI: 10.1161/JAHA.123.030714
View
- Share
Articles
Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease
Mok Y, Dardari Z, Sang Y, et al.
Journal:
J Am Coll Cardiol

First published: February 6, 2024 DOI: 10.1016/j.jacc.2023.11.028
View
- Share
Articles
Safety and Efficacy of PCSK9 Inhibitors in Patients with Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Grafts: A Comparative Retrospective Analysis
Nasso G, Larosa C, Bartolomucci F, et al.
Journal:
J Clin Med

First published: February 4, 2024 DOI: 10.3390/jcm13030907
View
- Share
Articles
Bempedoic acid: new evidence and recommendations on use
Paponja K, Pećin I, Reiner Ž, et al.
Journal:
Curr Opin Lipidol

First published: February 1, 2024 DOI: 10.1097/MOL.0000000000000911
View
- Share

1 … 5 6 7 8 9 … 12

Collection 4 (Sep 2023 - Aug 2024) Articles

Articles

Association of cardiovascular health with subclinical coronary atherosclerosis progression among five racial and ethnic groups: The MASALA and MESA studies

Jain V, Rifai MA, Kanaya AM, et al.

Articles

Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study

Alonso R, Arroyo-Olivares R, Díaz-Díaz JL, et al.

Articles

Oral PCSK9 Inhibitors

Agarwala A, Asim R, Ballantyne CM

Articles

European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges

3Pirillo A, Tokgözoğlu L, Catapano AL

Articles

Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?

Thau H, Neuber S, Emmert MY, et al.

Articles

Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials

Xie S, Galimberti F, Olmastroni E, et al.

Articles

Assessing the Role of Bempedoic Acid in Lipid-Lowering Therapy

Fernandez-Vazquez D, Weideman S, Banerjee S

Articles

Impact of the 2021 ESC Prevention Guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established ASCVD

Holtrop J, Bhatt DL, Ray KK, et al.

Articles

Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Bétrisey S, Haller ML, Efthimiou O, et al.

Articles

Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease

Mok Y, Dardari Z, Sang Y, et al.

Articles

Safety and Efficacy of PCSK9 Inhibitors in Patients with Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Grafts: A Comparative Retrospective Analysis

Nasso G, Larosa C, Bartolomucci F, et al.

Articles

Bempedoic acid: new evidence and recommendations on use

Paponja K, Pećin I, Reiner Ž, et al.

Articles

Association of cardiovascular health with subclinical coronary atherosclerosis progression among five racial and ethnic groups: The MASALA and MESA studies

Jain V, Rifai MA, Kanaya AM, et al.

Share

Articles

Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study

Alonso R, Arroyo-Olivares R, Díaz-Díaz JL, et al.

Share

Articles

Oral PCSK9 Inhibitors

Agarwala A, Asim R, Ballantyne CM

Share

Articles

European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges

3Pirillo A, Tokgözoğlu L, Catapano AL

Share

Articles

Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?

Thau H, Neuber S, Emmert MY, et al.

Share

Articles

Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials

Xie S, Galimberti F, Olmastroni E, et al.

Share

Articles

Assessing the Role of Bempedoic Acid in Lipid-Lowering Therapy

Fernandez-Vazquez D, Weideman S, Banerjee S

Share

Articles

Impact of the 2021 ESC Prevention Guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established ASCVD

Holtrop J, Bhatt DL, Ray KK, et al.

Share

Articles

Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Bétrisey S, Haller ML, Efthimiou O, et al.

Share

Articles

Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease

Mok Y, Dardari Z, Sang Y, et al.

Share

Articles

Safety and Efficacy of PCSK9 Inhibitors in Patients with Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Grafts: A Comparative Retrospective Analysis

Nasso G, Larosa C, Bartolomucci F, et al.

Share

Articles

Bempedoic acid: new evidence and recommendations on use

Paponja K, Pećin I, Reiner Ž, et al.

Share